Skip to main content

Table 1 Comparison of patient characteristics in the full study populations and the biomarker study eligible populations

From: A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab

  Discovery Validation
Full study population Biomarker population Full study population Biomarker population
Number of patients 250 150 328 210
Age, median (range) years 53 (18–89) 53 (18–89) 57 (22–90) 59 (22–90)
Gender, n (%)
 Male 151 (60%) 94 (63%) 190 (58%) 117 (56%)
 Female 99 (40%) 56 (37%) 138 (42%) 93 (44%)
Objective Response, n (%)
 Partial response 16 (7%) 20 (13%) 36 (11%) 28 (13%)
 Stable disease or progressive disease 235 (93%) 130 (87%) 292 (89%) 182 (87%)
Grade of diarrhea
 Any grade 99 (39%) 60 (40%) 166 (51%) 92 (44%)
 Grade 2–4 50 (20%) 21 (14%) 89 (27%) 56 (27%)
 Grade 3–4 37 (15%) 9 (6%) 60 (18%) 27 (13%)
 Prior chemotherapy Yes Yes No No
One year survival n (%)
 Patient alive at one year 100 (40%) 43 (29%) 170 (52%) 118 (56%)
 Patient deceased at one year 150 (60%) 107 (71%) 158 (48%) 92 (44%)
Stages of Disease
 IIIB and IIIC 8 (3%) 5 (3%) 20 (6%) 13 (6%)
 IV M1A 27 (11%) 16 (11%) 46 (14%) 35 (17%)
 IV M1B 52 (21%) 30 (20%) 75 (23%) 49 (23%)
 IV M1C 164 (65%) 99 (66%) 187 (57%) 113 (54%)
Live in United States n (%)
 U.S. 114 (46%) 62 (41%) 62 (19%) 44 (21%)
 Non-U.S. 136 (54%) 88 (59%) 266 (81%) 166 (795)